These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 11319588)
1. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588 [TBL] [Abstract][Full Text] [Related]
2. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790 [TBL] [Abstract][Full Text] [Related]
3. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302 [TBL] [Abstract][Full Text] [Related]
4. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921 [TBL] [Abstract][Full Text] [Related]
5. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Jantunen E; Mahlamäki E; Nousiainen T Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654 [TBL] [Abstract][Full Text] [Related]
6. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience. Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305 [TBL] [Abstract][Full Text] [Related]
7. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Escalón MP; Stefanovic A; Venkatraman A; Pereira D; Santos ES; Goodman M; Byrnes JJ; Fernandez HF Bone Marrow Transplant; 2009 Jul; 44(2):89-96. PubMed ID: 19169287 [TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen. Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724 [TBL] [Abstract][Full Text] [Related]
10. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF; J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447 [TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Jantunen E; Itälä M; Juvonen E; Leppä S; Keskinen L; Vasala K; Remes K; Wiklund T; Elonen E; Nousiainen T Bone Marrow Transplant; 2006 Feb; 37(4):367-72. PubMed ID: 16415893 [TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Salar A; Sierra J; Gandarillas M; Caballero MD; Marín J; Lahuerta JJ; García-Conde J; Arranz R; León A; Zuazu J; García-Laraña J; López-Guillermo A; Sanz MA; Grañena A; García JC; Conde E; Bone Marrow Transplant; 2001 Feb; 27(4):405-12. PubMed ID: 11313670 [TBL] [Abstract][Full Text] [Related]
13. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality. Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540 [TBL] [Abstract][Full Text] [Related]
14. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Wildes TM; Augustin KM; Sempek D; Zhang QJ; Vij R; Dipersio JF; Devine SM Biol Blood Marrow Transplant; 2008 Jul; 14(7):840-6. PubMed ID: 18541205 [TBL] [Abstract][Full Text] [Related]
15. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929 [TBL] [Abstract][Full Text] [Related]
16. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Kim JG; Sohn SK; Chae YS; Yang DH; Lee JJ; Kim HJ; Shin HJ; Jung JS; Kim WS; Kim DH; Suh C; Kim SJ; Eom HS; Bae SH Bone Marrow Transplant; 2007 Nov; 40(10):919-24. PubMed ID: 17846602 [TBL] [Abstract][Full Text] [Related]
17. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY; Horning SJ; Wong RM; Johnston LJ; Laport GG; Lowsky R; Shizuru JA; Blume KG; Negrin RS; Stockerl-Goldstein KE Biol Blood Marrow Transplant; 2006 Jul; 12(7):703-11. PubMed ID: 16785059 [TBL] [Abstract][Full Text] [Related]